Iran firmly denies rumors of secret negotiations and accuses The New York Times of engaging in "psychological warfare"
Odaily reported that Iran has denied reports claiming its intelligence ministry has contacted the United States to discuss ending the war in the Middle East. The New York Times previously reported that Iranian agents had indirectly contacted the CIA on Sunday to discuss terms for ending the conflict. According to the semi-official Tasnim News Agency, sources from Iran's intelligence ministry called the report "pure lies and psychological warfare." Following this denial, oil prices briefly surged but quickly retreated as traders shifted their focus to the U.S. Navy's plan to escort oil tankers through the Strait of Hormuz. Since the U.S. and Israel attacked Iran on Saturday, triggering the war, traffic through this critical chokepoint has sharply decreased. Publicly, both Iran and the U.S. have vowed to continue fighting, increasing the likelihood of a prolonged conflict in the Middle East. So far, the clashes have resulted in over 1,000 deaths (mainly within Iran). (Golden Ten Data)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure
Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.
Gold Price Forecast: XAU/USD retraces gains and nears two-month lows at $4,104
BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
Crypto prices
More
